In a groundbreaking development, the U.S. Food and Drug Administration’s first preliminary study on kratom has yielded surprising results. The research indicates that kratom leaves appear safe even at high doses when consumed in capsule form, challenging previous concerns about the botanical compound’s safety.
This study marks a significant step in understanding kratom, which has been used for centuries in Southeast Asia. However, the FDA cautions that important questions remain unanswered, particularly regarding kratom’s effects when consumed in drinks and concentrates, which are more common in the U.S. and potentially more potent.
The findings could have far-reaching implications for the regulation and perception of kratom in the United States. As research continues, this initial study may pave the way for a more nuanced approach to kratom policy and consumer safety guidelines.
